Cargando…
Neoantigens in Hematological Malignancies—Ultimate Targets for Immunotherapy?
Neoantigens derive from non-synonymous somatic mutations in malignant cells. Recognition of neoantigens presented via human leukocyte antigen (HLA) molecules on the tumor cell surface by T cells holds promise to enable highly specific and effective anti-cancer immune responses and thus neoantigens p...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6934135/ https://www.ncbi.nlm.nih.gov/pubmed/31921218 http://dx.doi.org/10.3389/fimmu.2019.03004 |